Asterias Biotherapeutics Inc (AST) Stock Rating Lowered by Zacks Investment Research
Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.
According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “
A number of other analysts have also recently weighed in on the stock. ValuEngine cut shares of Asterias Biotherapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 4th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Asterias Biotherapeutics in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $9.19.
Asterias Biotherapeutics (AST) traded up $0.05 during mid-day trading on Wednesday, reaching $2.55. 99,800 shares of the company traded hands, compared to its average volume of 163,781. Asterias Biotherapeutics has a 52 week low of $2.00 and a 52 week high of $5.70.
TRADEMARK VIOLATION WARNING: “Asterias Biotherapeutics Inc (AST) Stock Rating Lowered by Zacks Investment Research” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/22/asterias-biotherapeutics-inc-ast-stock-rating-lowered-by-zacks-investment-research.html.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.